What You Should Know:
- Exscientia, leading AI drug discovery company, today announced that it completed its $100 million Series C financing round, with a further $30 million investment from Blackrock.
- This new capital, which will be used to support Exscientia's platform development and proprietary pipeline, follows Exscientia’s demonstrated high growth, having announced earlier this year that the first ever precision engineered drug designed using AI had entered Phase I human clinical
Read More
Drug Discovery | Pharma |News, Analysis, Insights - HIT Consultant
Microsoft, UCB Launch Collaboration to Accelerate Drug Discovery and Development
What You Should Know:
- Global biopharma company UCB and Microsoft announced today a new, multi-year strategic collaboration to advance UCB’s digital transformation, change the way care is delivered, and accelerate better outcomes for people living with severe diseases.
- The partnership builds on the companies’ joint work as part of the COVID Moonshot project which sought to create an orally bioavailable anti-viral for COVID-19. During the project, UCB completed six
Read More
30 Executives Share Top Healthcare Predictions & Trends to Watch in 2021
As we close out the year, we asked several healthcare executives to share their predictions and trends for 2021.
Kimberly Powell, Vice President & General Manager, NVIDIA Healthcare
Federated Learning: The clinical community will increase their use of federated learning approaches to build robust AI models across various institutions, geographies, patient demographics, and medical scanners. The sensitivity and selectivity of these models are outperforming AI models
Read More
Backed by Khosla Ventures, Rubedo Life Sciences Secures $12M for Drug Discovery Platform
What You Should Know:
- Biopharma startup Rubedo Life Sciences raises $12M to develop a broad portfolio of innovative therapies engineered to target cells for chronic age-related diseases.
- Rubedo’s proprietary ALEMBIC™ drug discovery platform, has generated a novel pipeline of therapeutic candidates that selectively target senescent cells, pro-inflammatory and pro-fibrotic cell populations that result from a variety of cellular stress and damage.
Rubedo Life Sciences, a
Read More
Johnson & Johnson Innovation Launches 3 Collaborations to Advance Healthcare in China
What You Should Know:
- Johnson & Johnson Innovation announces three strategic
collaborations with a focus on advancing healthcare solutions in China.
- The three strategic collaborations are focused on leveraging advances in science and technology to address areas of high unmet medical need across several areas, including discovery science, lung cancer, and medical devices
Johnson & Johnson Innovation, a division of Johnson & Johnson (China) Investment Limited, today
Read More
Mission Bio Launches Single-Cell Multi-Omics System for Precision Cancer Therapies
What You Should Know:
- Mission Bio launches industry’s first and only
single-cell multi-omics platform, is announcing the launch of its most
comprehensive instrument to-date, to save the industry billions of dollars in
drug development costs and bring life-saving treatments to market at least six months
faster.
- Mission Bio’s Tapestri Platform, the first single-cell platform capable of detecting DNA and protein changes simultaneously, gives a profound insight into the mutations that
Read More
JPC Taps Proscia to Modernize World’s Largest Human Tissue Repository
What You Should Know:
- The U.S. government’s Joint Pathology Center, which
houses the world’s largest human tissue repository, today announced that
Proscia, a leading digital and AI pathology company, will provide end-to-end
modernization of JPC’s pathology operations.
- The multi-phase project will digitize the world’s
largest human pathology specimen repository in order to enhance biomedical
research for cancer and infectious diseases like COVID-19, and enable easier
data sharing with
Read More
4 Areas Driving AI Adoption in Hospital Operations and Patient Safety
COVID-19 has put a tremendous burden on hospitals, and the clinicians, nurses, and medical staff who make them run.
Many hospitals have suffered financially as they did not anticipate the severity of the disease. The extended duration of patient stays in ICUs, the need for more isolated rooms and beds, and the need for better supplies to reduce infections have all added costs. Some hospitals did not have adequate staff to check-in patients, take their temperature, monitor them regularly, or
Read More
Analysis: August Health IT M&A Activity; Public Company Performance
– Healthcare Growth Partners’ (HGP) summary of Health IT/digital health mergers & acquisition (M&A) activity, and public company performance during the month of August 2020.
M&A is back and the velocity of the rebound has outpaced all expectations. The recovery quickly worked its way across the spectrum from large to small-cap, beginning with the larger cap NASDAQ rally of nearly 80% from lows in late March (only to soften in recent days), followed by multi-billion
Read More
Scripps Research, Repurpose.AI Partner to Develop COVID-19 Therapeutics
What You Should Know:
- Repurpose.AI, has partnered with Scripps Research to
discover drug candidates that may be repurposed to treat COVID-19.
- The partnership will leverage Repurpose.AI's ActivPred
AI Drug Discovery Platform, an unbiased drug, target, and disease agnostic
digital chemistry engine, to discover drug candidates to treat COVID-19.
Scripps Research is
teaming up with Repurpose.AI, an AI
drug discovery company to develop COVID-19 therapeutics. The
Read More
